Weight Gain, Raised BP Risk Seen for HIV Patients Switching to Dolutegravir
Patients switching from efavirenz to dolutegravir gain more weight at 12 months and have increased risk for hypertension
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.